Background and goal: Diarrhoea-predominant irritable bowel syndrome (IBS-D) exhibits intestinal innate immune and mucosal mast cell (MC) activation. MC stabilisers have been shown to improve IBS symptoms but the mechanism is unclear. Our primary aim was to investigate the effect of oral disodium cromoglycate (DSCG) on jejunal MC activation and specific innate immune signalling pathways in IBS-D, and secondarily, its potential clinical benefit.
Study: Mucosal MC activation (by ultrastructural changes, tryptase release and gene expression) and innate immune signalling (by protein and gene expression) were quantified in jejunal biopsies from healthy (HS; n = 16) and IBS-D subjects after six months of either treatment with DSCG (600 mg/day, IBS-D-DSCG group; n = 18) or without treatment (IBS-D-NT group; n = 25). All IBS-D patients recorded abdominal pain and bowel habits at baseline and in the last 10 days prior to jejunal sampling.
Results: IBS-D-NT exhibited significant MC activation and over-expression of immune-related genes as compared to HS, whereas in IBS-D-DSCG MC activity and gene expression were similar to HS. Furthermore, DSCG significantly reduced abdominal pain and improved stool consistency.
Conclusion: Oral DSCG modulates mucosal immune activity and improves gut symptoms in IBS-D patients. Future placebo-controlled clinical trials are needed for confirmation of clinical benefit of DSCG for IBS-D.
Keywords: Diarrhea-predominant irritable bowel syndrome; Toll-like receptors; disodium cromoglycate; intestinal innate immunity; mast cell.
Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.Gut. 2013 Aug;62(8):1160-8. doi: 10.1136/gutjnl-2012-302093. Epub 2012 May 25. Gut. 2013. PMID: 22637702
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.Trials. 2013 Jan 9;14:10. doi: 10.1186/1745-6215-14-10. Trials. 2013. PMID: 23302220 Free PMC article. Clinical Trial.
Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations.Gut. 2015 Sep;64(9):1379-88. doi: 10.1136/gutjnl-2013-306236. Epub 2014 Sep 10. Gut. 2015. PMID: 25209656
Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside.J Neurogastroenterol Motil. 2016 Apr 30;22(2):181-92. doi: 10.5056/jnm15137. J Neurogastroenterol Motil. 2016. PMID: 26755686 Free PMC article. Review.
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11. Pharmacotherapy. 2016. PMID: 26971716 Review.
Cited by 4 articles
Potential neuro-immune therapeutic targets in irritable bowel syndrome.Therap Adv Gastroenterol. 2020 Apr 9;13:1756284820910630. doi: 10.1177/1756284820910630. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 32313554 Free PMC article. Review.
Atopic Patients Who Fulfilled Rome III Criteria for Irritable Bowel Syndrome Had Higher Animal Danders Sensitization.J Neurogastroenterol Motil. 2020 Apr 30;26(2):267-273. doi: 10.5056/jnm19181. J Neurogastroenterol Motil. 2020. PMID: 32235034 Free PMC article.
Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function.Cells. 2019 Feb 22;8(2):193. doi: 10.3390/cells8020193. Cells. 2019. PMID: 30813280 Free PMC article. Review.
Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis.Cells. 2019 Feb 8;8(2):135. doi: 10.3390/cells8020135. Cells. 2019. PMID: 30744042 Free PMC article. Review.